| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Accrual by groups in trials with discrete-time survival endpoints
|
Jóźwiak, Katarzyna
|
|
2013
|
10 |
1 |
p. 32-42
|
artikel
|
| 2 |
Assessing the usefulness of health data linkage in obtaining adverse event data in a randomised controlled trial of oral and implant naltrexone in the treatment of heroin dependence
|
Kelty, Erin
|
|
2013
|
10 |
1 |
p. 170-180
|
artikel
|
| 3 |
A systematic review of on-site monitoring methods for health-care randomised controlled trials
|
Macefield, Rhiannon C
|
|
2013
|
10 |
1 |
p. 104-124
|
artikel
|
| 4 |
Bayesian adaptive design for device surveillance
|
Murray, Thomas A
|
|
2013
|
10 |
1 |
p. 5-18
|
artikel
|
| 5 |
Clinician-trialist rounds: 14. Ways to advance your career by saying ‘no’ – part 2: When to say ‘no’, and why
|
Oxman, Andrew D
|
|
2013
|
10 |
1 |
p. 181-187
|
artikel
|
| 6 |
Commentary on ‘Small-sample behavior of novel phase I cancer trial designs’
|
Cheung, Ying Kuen
|
|
2013
|
10 |
1 |
p. 86-87
|
artikel
|
| 7 |
Conducting the ACTIVE randomized trial in hospice care: Keys to success
|
Kruse, Robin L
|
|
2013
|
10 |
1 |
p. 160-169
|
artikel
|
| 8 |
Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study
|
Babiker, Abdel G
|
|
2013
|
10 |
1 |
p. S5-S36
|
artikel
|
| 9 |
Cost–utility analysis conducted alongside randomized controlled trials: Are economic end points considered in sample size calculations and does it matter?
|
Hollingworth, William
|
|
2013
|
10 |
1 |
p. 43-53
|
artikel
|
| 10 |
Determining optimal sample sizes for multistage adaptive randomized clinical trials from an industry perspective using value of information methods
|
Chen, Maggie H
|
|
2013
|
10 |
1 |
p. 54-62
|
artikel
|
| 11 |
Discussion of ‘Small-sample behavior of novel phase I cancer trial designs’ by Assaf P Oron and Peter D Hoff
|
Carlin, Bradley P
|
|
2013
|
10 |
1 |
p. 81-85
|
artikel
|
| 12 |
Efficiency of using community organisations as catalysts for recruitment to continence promotion trials
|
Agnew, Rona
|
|
2013
|
10 |
1 |
p. 151-159
|
artikel
|
| 13 |
Meta-analysis of clinical trial safety data in a drug development program: Answers to frequently asked questions
|
Berlin, Jesse A
|
|
2013
|
10 |
1 |
p. 20-31
|
artikel
|
| 14 |
Moving a randomized clinical trial into an observational cohort
|
Goodman, Phyllis J
|
|
2013
|
10 |
1 |
p. 131-142
|
artikel
|
| 15 |
Obtaining surrogate consent for a minimal-risk research study in the intensive care unit setting
|
Larkin, Mary E
|
|
2013
|
10 |
1 |
p. 93-96
|
artikel
|
| 16 |
2012 Peer Reviewers
|
|
|
2013
|
10 |
1 |
p. 188-190
|
artikel
|
| 17 |
Small-sample behavior of novel phase I cancer trial designs
|
Oron, Assaf P
|
|
2013
|
10 |
1 |
p. 63-80
|
artikel
|
| 18 |
Small-sample behavior of novel phase I designs: Rejoinder
|
Oron, Assaf P
|
|
2013
|
10 |
1 |
p. 88-92
|
artikel
|
| 19 |
Unblinding following trial participation: Qualitative study of participants’ perspectives
|
Armstrong, Natalie
|
|
2013
|
10 |
1 |
p. 97-103
|
artikel
|
| 20 |
Usefulness of prestudy assessment of patient willingness to undergo tissue biopsy for correlative studies in a melanoma vaccine trial
|
Judge, Joshua M
|
|
2013
|
10 |
1 |
p. 143-150
|
artikel
|
| 21 |
Using scratch card technology for random allocation concealment in a clinical trial with a crossover design
|
Beksinska, Mags E
|
|
2013
|
10 |
1 |
p. 125-130
|
artikel
|
Tijdschrift beschrijving